Literature DB >> 31801862

Impact of Suboptimal APOBEC3G Neutralization on the Emergence of HIV Drug Resistance in Humanized Mice.

Matthew M Hernandez1,2, Audrey Fahrny3, Ravi Sachidanandam4, Roberto F Speck3, Viviana Simon5,6,7, Anitha Jayaprakash4, Gustavo Gers-Huber3, Marsha Dillon-White2, Annette Audigé3, Lubbertus C F Mulder2,6.   

Abstract

HIV diversification facilitates immune escape and complicates antiretroviral therapy. In this study, we take advantage of a humanized-mouse model to probe the contribution of APOBEC3 mutagenesis to viral evolution. Humanized mice were infected with isogenic HIV molecular clones (HIV-WT, HIV-45G, and HIV-ΔSLQ) that differ in their abilities to counteract APOBEC3G (A3G). Infected mice remained naive or were treated with the reverse transcriptase (RT) inhibitor lamivudine (3TC). Viremia, emergence of drug-resistant variants, and quasispecies diversification in the plasma compartment were determined throughout infection. While both HIV-WT and HIV-45G achieved robust infection, over time, HIV-45G replication was significantly reduced compared to that of HIV-WT in the absence of 3TC treatment. In contrast, treatment responses differed significantly between HIV-45G- and HIV-WT-infected mice. Antiretroviral treatment failed in 91% of HIV-45G-infected mice, while only 36% of HIV-WT-infected mice displayed a similar negative outcome. Emergence of 3TC-resistant variants and nucleotide diversity were determined by analyzing 155,462 single HIV reverse transcriptase gene (RT) and 6,985 vif sequences from 33 mice. Prior to treatment, variants with genotypic 3TC resistance (RT-M184I/V) were detected at low levels in over a third of all the animals. Upon treatment, the composition of the plasma quasispecies rapidly changed, leading to a majority of circulating viral variants encoding RT-184I. Interestingly, increased viral diversity prior to treatment initiation correlated with higher plasma viremia in HIV-45G-infected animals, but not in HIV-WT-infected animals. Taken together, HIV variants with suboptimal anti-A3G activity were attenuated in the absence of selection but displayed a fitness advantage in the presence of antiretroviral treatment.IMPORTANCE Both viral (e.g., RT) and host (e.g., A3G) factors can contribute to HIV sequence diversity. This study shows that suboptimal anti-A3G activity shapes viral fitness and drives viral evolution in the plasma compartment in humanized mice.
Copyright © 2020 American Society for Microbiology.

Entities:  

Keywords:  APOBEC3; HIV Vif; HIV diversification; HIV drug resistance; human immunodeficiency virus; humanized mice; virus-host interactions

Mesh:

Substances:

Year:  2020        PMID: 31801862      PMCID: PMC7022346          DOI: 10.1128/JVI.01543-19

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  91 in total

Review 1.  HIV-1 drug resistance: can we overcome?

Authors:  Bluma G Brenner; Dan Turner; Mark A Wainberg
Journal:  Expert Opin Biol Ther       Date:  2002-10       Impact factor: 4.388

2.  APOBEC3G and APOBEC3F Act in Concert To Extinguish HIV-1 Replication.

Authors:  John F Krisko; Nurjahan Begum; Caroline E Baker; John L Foster; J Victor Garcia
Journal:  J Virol       Date:  2016-04-14       Impact factor: 5.103

3.  The role of steric hindrance in 3TC resistance of human immunodeficiency virus type-1 reverse transcriptase.

Authors:  H Q Gao; P L Boyer; S G Sarafianos; E Arnold; S H Hughes
Journal:  J Mol Biol       Date:  2000-07-07       Impact factor: 5.469

4.  Remarkable lethal G-to-A mutations in vif-proficient HIV-1 provirus by individual APOBEC3 proteins in humanized mice.

Authors:  Kei Sato; Taisuke Izumi; Naoko Misawa; Tomoko Kobayashi; Yoshiki Yamashita; Masahide Ohmichi; Mamoru Ito; Akifumi Takaori-Kondo; Yoshio Koyanagi
Journal:  J Virol       Date:  2010-07-07       Impact factor: 5.103

Review 5.  In Vivo Models of Human Immunodeficiency Virus Persistence and Cure Strategies.

Authors:  Christopher C Nixon; Maud Mavigner; Guido Silvestri; J Victor Garcia
Journal:  J Infect Dis       Date:  2017-03-15       Impact factor: 5.226

6.  One percent tenofovir applied topically to humanized BLT mice and used according to the CAPRISA 004 experimental design demonstrates partial protection from vaginal HIV infection, validating the BLT model for evaluation of new microbicide candidates.

Authors:  Paul W Denton; Florence Othieno; Francisco Martinez-Torres; Wei Zou; John F Krisko; Elisa Fleming; Sima Zein; Daniel A Powell; Angela Wahl; Youn Tae Kwak; Brett D Welch; Michael S Kay; Deborah A Payne; Philippe Gallay; Ettore Appella; Jacob D Estes; Min Lu; J Victor Garcia
Journal:  J Virol       Date:  2011-05-18       Impact factor: 5.103

7.  Human APOBEC3G-mediated editing can promote HIV-1 sequence diversification and accelerate adaptation to selective pressure.

Authors:  Eun-Young Kim; Tanmoy Bhattacharya; Kevin Kunstman; Peter Swantek; Fransje A Koning; Michael H Malim; Steven M Wolinsky
Journal:  J Virol       Date:  2010-07-21       Impact factor: 5.103

8.  Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection.

Authors:  Brandon F Keele; Elena E Giorgi; Jesus F Salazar-Gonzalez; Julie M Decker; Kimmy T Pham; Maria G Salazar; Chuanxi Sun; Truman Grayson; Shuyi Wang; Hui Li; Xiping Wei; Chunlai Jiang; Jennifer L Kirchherr; Feng Gao; Jeffery A Anderson; Li-Hua Ping; Ronald Swanstrom; Georgia D Tomaras; William A Blattner; Paul A Goepfert; J Michael Kilby; Michael S Saag; Eric L Delwart; Michael P Busch; Myron S Cohen; David C Montefiori; Barton F Haynes; Brian Gaschen; Gayathri S Athreya; Ha Y Lee; Natasha Wood; Cathal Seoighe; Alan S Perelson; Tanmoy Bhattacharya; Bette T Korber; Beatrice H Hahn; George M Shaw
Journal:  Proc Natl Acad Sci U S A       Date:  2008-05-19       Impact factor: 11.205

9.  HIV-1 competition experiments in humanized mice show that APOBEC3H imposes selective pressure and promotes virus adaptation.

Authors:  Yusuke Nakano; Naoko Misawa; Guillermo Juarez-Fernandez; Miyu Moriwaki; Shinji Nakaoka; Takaaki Funo; Eri Yamada; Andrew Soper; Rokusuke Yoshikawa; Diako Ebrahimi; Yuuya Tachiki; Shingo Iwami; Reuben S Harris; Yoshio Koyanagi; Kei Sato
Journal:  PLoS Pathog       Date:  2017-05-05       Impact factor: 6.823

Review 10.  A step forward understanding HIV-1 diversity.

Authors:  Redmond P Smyth; Matteo Negroni
Journal:  Retrovirology       Date:  2016-04-19       Impact factor: 4.602

View more
  7 in total

1.  Impact of Suboptimal APOBEC3G Neutralization on the Emergence of HIV Drug Resistance in Humanized Mice.

Authors:  Matthew M Hernandez; Audrey Fahrny; Ravi Sachidanandam; Roberto F Speck; Viviana Simon; Anitha Jayaprakash; Gustavo Gers-Huber; Marsha Dillon-White; Annette Audigé; Lubbertus C F Mulder
Journal:  J Virol       Date:  2020-02-14       Impact factor: 5.103

2.  Drug resistance mutations in HIV provirus are associated with defective proviral genomes with hypermutation.

Authors:  Yijia Li; Behzad Etemad; Ruth Dele-Oni; Radwa Sharaf; Ce Gao; Mathias Lichterfeld; Jonathan Z Li
Journal:  AIDS       Date:  2021-06-01       Impact factor: 4.632

Review 3.  Structural Insights into APOBEC3-Mediated Lentiviral Restriction.

Authors:  Krista A Delviks-Frankenberry; Belete A Desimmie; Vinay K Pathak
Journal:  Viruses       Date:  2020-05-27       Impact factor: 5.048

Review 4.  APOBECs and Herpesviruses.

Authors:  Adam Z Cheng; Sofia N Moraes; Nadine M Shaban; Elisa Fanunza; Craig J Bierle; Peter J Southern; Wade A Bresnahan; Stephen A Rice; Reuben S Harris
Journal:  Viruses       Date:  2021-02-28       Impact factor: 5.818

5.  Small-Angle X-ray Scattering (SAXS) Measurements of APOBEC3G Provide Structural Basis for Binding of Single-Stranded DNA and Processivity.

Authors:  Fareeda M Barzak; Timothy M Ryan; Nazanin Mohammadzadeh; Stefan Harjes; Maksim V Kvach; Harikrishnan M Kurup; Kurt L Krause; Linda Chelico; Vyacheslav V Filichev; Elena Harjes; Geoffrey B Jameson
Journal:  Viruses       Date:  2022-09-06       Impact factor: 5.818

Review 6.  Examination of the APOBEC3 Barrier to Cross Species Transmission of Primate Lentiviruses.

Authors:  Amit Gaba; Ben Flath; Linda Chelico
Journal:  Viruses       Date:  2021-06-07       Impact factor: 5.048

Review 7.  Human APOBEC3 Variations and Viral Infection.

Authors:  Shiva Sadeghpour; Saeideh Khodaee; Mostafa Rahnama; Hamzeh Rahimi; Diako Ebrahimi
Journal:  Viruses       Date:  2021-07-14       Impact factor: 5.818

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.